MAP2K7 and melanoma: Targeted therapy for patients whose tumors harbor the BRAFV600 mutation achieves high response rates and OS benefit with the combination BRAF/MEK inhibition and represents the ideal first-line treatment for patients with BRAF-mutated advanced melanoma.